Prediction of pneumonia following neoadjuvant chemoradiotherapy in patients with oesophageal cancer

BACKGROUND AND PURPOSE: Pneumonia is a frequent, severe complication following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy for oesophageal cancer, adversely affecting outcomes. We aimed to develop a model to accurately predict this risk. MATERIAL AND METHODS: This multicentre, retrospective study included oesophageal cancer patients (cT1-4N0-3M0) undergoing nCRT +/- esophagectomy (CROSS regimen) treated between 2015-2021. The endpoint was grade ≥2 pneumonia (CTCAE v5.0) within six months post-nCRT. To handle high dimensionality, principal component analysis (PCA) was used to condense lung and heart DVH patterns into interpretable dose patterns. A logistic regression model was developed and validated using internal-external cross-validation to assess discrimination, calibration, and heterogeneity across centres. RESULTS: = 0% for all measures), fair discrimination (pooled AUC 0.68; 95% CI, 0.63-0.72), and excellent calibration (slope 0.91; 95% CI, 0.56-1.26; calibration-in-the-large 0.02; 95% CI, -0.14-0.18). CONCLUSION: We developed and validated a generalizable NTCP model for pneumonia prediction in oesophageal cancer patients. This multicentre pulmonary NTCP model showed good calibration and homogeneous performance between centres. It offers a promising tool to personalize treatment by facilitating radiotherapy plan optimization and treatment/technique selection.

Authors

Institutions

Publication Details

Journal
Radiotherapy and Oncology
Published
2026-05-01
DOI
https://doi.org/10.1016/j.radonc.2026.111554
Primary Topic
Esophageal Cancer Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prediction of pneumonia following neoadjuvant chemoradiotherapy in patients with oesophageal cancer

J.J. Nuyttens, R. Canters, J Ruurda, M.L. Frederiks et al.
Radiotherapy and Oncology
Esophageal Cancer Research and Treatment
article

Prediction of pneumonia following neoadjuvant chemoradiotherapy in patients with oesophageal cancer

J.J. Nuyttens, R. Canters, J Ruurda, M.L. Frederiks, H. Rütten, G.J. Meijer, P.S.N. van Rossum, B. van Etten, B. Mostert, C.T. Muijsa, S. Mook, M.I. van Berge Henegouwen, M. Sosef, E. Schuit, M. Berbéeb, R.H.A. Verhoeven, B.P.L. Wijnhoven, B. Klarenbeek, Z. van Kesteren, J.A. Langendijk, M.D.den Hartogh, H.W.M. van Laarhoven
article en

Abstract

BACKGROUND AND PURPOSE: Pneumonia is a frequent, severe complication following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy for oesophageal cancer, adversely affecting outcomes. We aimed to develop a model to accurately predict this risk. MATERIAL AND METHODS: This multicentre, retrospective study included oesophageal cancer patients (cT1-4N0-3M0) undergoing nCRT +/- esophagectomy (CROSS regimen) treated between 2015-2021. The endpoint was grade ≥2 pneumonia (CTCAE v5.0) within six months post-nCRT. To handle high dimensionality, principal component analysis (PCA) was used to condense lung and heart DVH patterns into interpretable dose patterns. A logistic regression model was developed and validated using internal-external cross-validation to assess discrimination, calibration, and heterogeneity across centres. RESULTS: = 0% for all measures), fair discrimination (pooled AUC 0.68; 95% CI, 0.63-0.72), and excellent calibration (slope 0.91; 95% CI, 0.56-1.26; calibration-in-the-large 0.02; 95% CI, -0.14-0.18). CONCLUSION: We developed and validated a generalizable NTCP model for pneumonia prediction in oesophageal cancer patients. This multicentre pulmonary NTCP model showed good calibration and homogeneous performance between centres. It offers a promising tool to personalize treatment by facilitating radiotherapy plan optimization and treatment/technique selection.

Radiotherapy and Oncology
University Medical Center Groningen (NL), Radboud University Nijmegen (NL), Utrecht University (NL), Radboud University Medical Center (NL), University Medical Center Utrecht (NL), Amsterdam Neuroscience (NL), Zuyderland Medisch Centrum (NL), Netherlands Comprehensive Cancer Organisation (NL), Radiotherapiegroep (NL), Erasmus MC Cancer Institute (NL), Amsterdam University Medical Centers (NL), Maastro Clinic (NL)
KWF Kankerbestrijding
Peace, Justice and strong institutions
Openalex Percentile: Top 6%
Esophageal Cancer Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.